Treatment of cancer cells with a DNA breaking agent led to upregulation of immune-related pathways such as PD-1 and Interferon Signaling whereas this upregulation was either prevented or reversed by RAD51 inhibitor. The gene discussed is RAD51; the disease is cancer.